1 Company Overvie...12 Sales force 1,000+ About 70% : Doctors and Pharmacists Directly covering...

2

3

1 Company Overview

2 Hanmi R&D

3 Beijing Hanmi

4 Financial Results

5 Appendix

4

(Automated Drug Packaging System Company)

805.0

187.1 162.6 170.7

192.9 209.8

0

200

400

600

0

500

1,000

1,500

2015 2016 2017 2018 2019

Sales R&D

1,317.5(Incl. Upfront/Milestones)Sales

(bn KRW)R&D

(bn KRW)

14.2%18.4% 18.6%

19.0%18.8%

5

916.6882.7

1,016.0

1,113.6

Upfront/Milestones

6

7

8

AG

LYCO

SYLATED

FC

AG

LYCO

SYLATED

FC

AG

LYCO

SYLATED

FC

AG

LYCO

SYLATED

FC

Longer Duration

Efficacy & Safety ↑

9

Key Features

Seeking collaboration opportunities

Pre-clinical Phase 1 Phase 2 Phase 3 Registration

Obesity/NASH/Diabetes

LAPSGlucagon ComboHM14320Obesity/Diabetes/NASH

LAPSTriple AgonistHM15211NASH

LAPSGLP/GCGHM12525AObesity

LAPSExd4 AnalogEfpeglenatideDiabetes

LAPSInsulin ComboHM14220Diabetes

LAPSGlucagon AnalogHM15136Obesity

LAPInsulin148HM12480Diabetes

LAPSInsulinHM12460A/HM12470Diabetes

Oncology

EZH1/2 Inhibitor

Solid tumor

Pan-RAF InhibitorBelvarafenibSolid tumor

Pan-HER InhibitorPoziotinibSolid tumor

Oraxol™Paclitaxel+encequidarBreast cancer, solid tumor

LAPSGCSF AnalogEflapegrastimNeutropenia

LSD1 Inhibitor

SCLC, AML

FLT3 InhibitorHM43239AML

Oratecan™Irinotecan+encequidarSolid tumor

ADOR Antagonist

Solid tumor

PD-1/HER2 BsAbBH2950Solid tumor

Oradoxel™Docetaxel+encequidarSolid tumor

GBM Stem Cell TherapyHM21001Glioblastoma

FLX475 (CCR4 Inhibitor)

Solid tumor

Immuno-oncology BsAb

Solid tumor

PD-L1/CD47 BsAb

Solid tumor, Hematologic cancers

Rare Diseases/Other

LAPSASBHM15450Mucopolysaccharidosis

LAPSGlucagon AnalogHM15136Congenital Hyperinsulinism

LAPShGHEfpegsomatropinGH deficiency

LAPSGLP-2 AnalogHM15912Short Bowel Syndrome

Luminate®

Integrin inhibitorDME

Luminate®

Integrin inhibitorRetinitis Pigmentosa

BTK InhibitorHM71224Autoimmune disease 10

B

B

B

B Beijing Hanmi

11

Delivering double-digit growth in domestic market with core

value-added products

Launching 2~3 value-added products annually

Seeking partners for emerging markets

Domestic business growth

2019

Hanmi

597.6

551.8

2018

578.7

2017

526.8

2016

805.0882.7

916.6

1,016.0

675.4

1,113.6

2015

13.0%Korea

Total

Top value-added products

*IMD (Incrementally Modified Drug); **FDC (Fixed Dose Combination)

12

Sales force 1,000+

About 70% : Doctors and Pharmacists

Directly covering 9,000 hospitals and over

150,000 doctors, keeping the No.1

position in pediatric drug market.

Sales & MarketingManufacturingBeijing R&D center

New Biologics BIO ProductionNCE

- Auto-immune

- Oncology

- Diabetes

- Obesity

- Oncology

- PENTAMBODY

PhD. 5, MS. 74

Est. Oct 2008

Animal facility for rodents, beagles,

and primates

High-tech enterprise certification

Focus areas

R&D staffs 150+ GMP sites

To provide FPP to

Chinese market

13

14

15

DEC

16

17

18

19

164.839.90.012.2

20

21

22

24.2% 13.0%

39.7% 11.7%

16.4% -7.5%

12.1% -4.5%

21.0% 15.1%

35.1% 13.8%

12.9% -5.4%

8.8% -2.3%

23

22.2%

59.8%

70.9%

-15.3%

24

15.1% 10.5%

8.8% 5.8%

17.3% 13.9%

11.4% 7.6%

15.6% 8.1%

-7.9% -11.3%

7.2% -15.1%

13.4% 24.5%

25

26

27

28